EVE Health Group Advances ED Treatment with First Order for Libbo

EVE Health Group (ASX: EVE) has submitted its first commercial purchase order for Libbo, the company’s proprietary oral dissolving film treatment for erectile dysfunction (ED).

One of the company’s GMP-certified pharmaceutical partners received the order, and EVE expects first shipments to Australia in the December quarter.

EVE needs to make no further regulatory steps, paving the way for Libbo to be prescribed before the end of 2025.

Path to Commercial Launch

Libbo marks EVE’s first prescription pharmaceutical product in the men’s health category, and a critical milestone for the company’s pharmaceutical division.

The product leverages established active pharmaceutical ingredients in a new delivery format, highlighting EVE’s strategy to combine proven compounds with patient-friendly innovation.

The company noted that this order follows closely after the first commercial purchase order for Dyspro, demonstrating momentum across its prescription product pipeline.

Market Opportunity

Erectile dysfunction is a widespread condition affecting one in five men over 18 and an estimated 40% of men over 40.

Analysts currently value the global treatment market at more than US$5.3 billion and expect it to expand steadily, driven by shifting social attitudes and technological advances.

EVE said Libbo’s oral dissolving film format offers patients a discreet, convenient and fast-acting alternative to tablets, potentially lifting compliance and patient satisfaction.

Science-Led Innovation

Chief scientific officer Dr Stuart Gunzburg said the commercial order underscored EVE’s progress in translating science-led innovation into market-ready products.

“Placing our first commercial order for Libbo is a major step in delivering a high-quality, patient-friendly ED treatment to market,” Dr Gunzburg said.

He added that the product broadens EVE’s prescription portfolio into a key men’s health category, reinforcing the company’s capacity to develop and commercialise innovative pharmaceutical solutions.

Manufacture Underway

Manufacturing of Libbo has already commenced, with supply scheduled for the December quarter.

Authorised prescribers in EVE’s network will be able to prescribe the treatment immediately once available, without further regulatory processes.

The company said it will provide updates as production advances and preparations for market rollout near completion.